Search Results
Your search for all items matches 36901 pages
Showing 1 - 50Surviving Cancer Put Me On a Career Path in Cancer Research
I was just 24 and in seemingly perfect health when I began experiencing unexplained abdominal pain so excruciating, even daily doses of pain medication failed to provide relief. I was a senior in college and had enrolled in a summer internship program at the University of California, Davis, when my ...
20th Annual Award for Leadership in Personalized Medicine
The Personalized Medicine Coalition (PMC), a nonprofit organization dedicated to advancing personalized medicine, recently announced that physician-scientist Norman E. “Ned” Sharpless, MD, has been selected as the recipient of the 20th Annual Award for Leadership in Personalized Medicine,...
Envafolimab Regimen Improves Pathologic Complete Response in MSS Locally Advanced Rectal Cancer
Adding the subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX (capecitabine and oxaliplatin) improved pathologic complete response (pCR) without a clear safety or surgical feasibility penalty in patients with microsatellite-stable (MSS) locally advanced rectal cancer,...
‘Save Research’ Campaign Champions Federal Funding
ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline. “The People Behind the Progress,” an ASCO social media series, features members sharing how federal cancer research has...
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
The U.S. Food and Drug Administration (FDA) recently approved daraxonrasib, (Rasonque), a multiselective RAS(ON) inhibitor, for treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. ...
Structured Exercise After Adjuvant Chemotherapy for Colon Cancer Improves Survival and Saves Costs
A structured exercise program after adjuvant chemotherapy for colon cancer improved survival and saved money. In a preplanned cost-utility analysis of the phase III CHALLENGE trial, presented at the 2026 ASCO Annual Meeting1 and published simultaneously in the Journal of Clinical Oncology,2 the...
Long-Term Trial Supports Selective Use of Extended Pelvic Lymph Node Dissection in High-Grade Prostate Cancer
Extended pelvic lymph node dissection has long been used during radical prostatectomy to improve staging in men with higher-risk prostate cancer. Whether the more extensive operation also improves cancer outcomes has been less clear. New long-term randomized data presented at the 2026 American...
NSCLC: FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
ESMO Announces 2026 Society Award Recipients
The European Society for Medical Oncology (ESMO) has announced the recipients of the 2026 ESMO Society Awards, recognizing four outstanding oncology professionals whose contributions have advanced cancer research, enhanced clinical care, and strengthened the global oncology community. ESMO Award...
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
According to the results of a retrospective analysis reported by Jeong et al in JCO Precision Oncology, early molecular response assessed using circulating tumor DNA (ctDNA) was associated with radiographic response and longer time to progression among patients with recurrent high-grade serous...
SUO/AUA Updates Guidelines for Non–Muscle Invasive Bladder Cancer
The American Urologic Association (AUA), in partnership with the Society of Urologic Oncology (SUO) has released an amendment for 2026 to the Diagnosis and Treatment of Non–Muscle Invasive Bladder Cancer (NMIBC) Guideline, published in The Journal of Urology. The amendment introduces 40 new and...
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
A refined dynamic prognostic model incorporating longitudinal measurable residual disease (MRD) assessments may improve prediction of progression-free survival and overall survival in patients with chronic lymphocytic leukemia (CLL) receiving limited-duration therapy. The findings, reported by...
Robert A. Kyle, MD, Myeloma Expert, Dies at 98
The International Myeloma Foundation (IMF) shared news of the passing of Robert A. Kyle, MD, at age 98 on September 2, 2026. Dr. Kyle was a highly revered expert in the field of myeloma research and known to many as the “Father of Myeloma” for his groundbreaking work in hematology. Dr. Kyle was...
Prostate Cancer: Higher Saturated Fat Intake May Be Linked to Worse Outcomes
Patients with nonmetastatic prostate cancer who consumed higher quantities of saturated fats, including animal fats, had a higher risk of all-cause mortality, including death from cardiovascular disease and other cancer, according to the results of a study published in JAMA Network Open. “Our...
Long-Course Chemoradiotherapy Shows Early Organ Preservation Advantage in Rectal Cancer
Long-course chemoradiotherapy resulted in superior 12-month total mesorectal excision–free survival compared with short-course radiotherapy in the STAR-TREC trial. The interim analysis, led by Simon P. Bach, FRCS, and colleagues and published in The Lancet Oncology, included patients pursuing organ ...
Duane A. Mitchell, MD, PhD, Named Director of the UF Health Cancer Institute
The University of Florida has selected Duane A. Mitchell, MD, PhD, as the next Director of the UF Health Cancer Institute. Dr. Mitchell, the Phyllis Kottler Friedman Professor in the Department of Neurosurgery, assumes the role September 21 at a pivotal moment for the institute, which earned...
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
On September 4, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, HER2-negative...
AI Applied to Mammograms May Help Identify Common Cardiovascular Conditions
In addition to searching for breast cancer, artificial intelligence (AI) used in mammography reads may help to detect common cardiovascular diseases, according to study findings presented at the ESC Congress 2026. “Because mammography is already widely used, analyzing the same images for...
Prostate Cancer: Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care
A set of uncontrolled, modifiable cardiovascular risk factors may help identify a subgroup of patients with prostate cancer who could benefit from additional cardiovascular care, according to findings published in JACC: CardioOncology and presented at the ESC Congress 2026. “The major findings...
Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain
Over the past 75 years, advances in the treatment of major blood cancers have saved more than 25 million years of life in the United States, according to results of an analysis led by researchers at Blood Cancer United and published by Chang et al in Blood Advances. But the gains have not reached...
Cervical Cancer Nonscreening Increased Over Nearly 2 Decades
Cervical cancer remains a preventable cause of morbidity and mortality, particularly among women who are not reached by screening programs. In a research letter published in JAMA Network Open, Sonawane et al emphasized the importance of identifying those who have never been screened and reported...
Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer
Secondary analyses of the prospective EA1181/CompassHER2 pCR trial identified clinicopathologic and molecular factors associated with pathologic complete response (pCR) after de-escalated neoadjuvant therapy with a taxane plus trastuzumab and pertuzumab (THP) in patients with stage II to IIIA...
Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer
The first clinical evaluation of the chemotherapy-free combination of ifebemtinib and garsorasib showed encouraging antitumor activity in patients with previously treated KRAS G12C–mutated metastatic colorectal cancer, although the improvement in objective response rate over garsorasib alone did...
Researchers Define Molecular, Prognostic Subgroups in Therapy-Related Myeloid Neoplasms
Identifying germline genetic variants in patients with therapy-related myeloid neoplasms revealed distinct molecular and prognostic subgroups with distinct outcomes, according to research findings published in Blood Advances. The findings could help to guide physicians in determining which patients ...
Hypofractionated Salvage Radiotherapy Evaluated After Prostatectomy for Biochemical Recurrence
According to interim results of the phase III SHARE trial reported by Song et al in the Journal of Clinical Oncology, hypofractionated salvage radiotherapy produced similar 4-year oncologic outcomes to conventional radiotherapy among patients with biochemical recurrence after radical prostatectomy, ...
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
The combination of the epidermal growth factor receptor (EGFR)-directed antibody-drug conjugate (ADC) becotatug vedotin and the PD-1 inhibitor pucotenlimab demonstrated antitumor activity in patients with recurrent or metastatic nasopharyngeal carcinoma previously treated with platinum-based...
ACS Publishes Report on Cancers in Asian American, Native Hawaiian, and Pacific Islander People
Cancer data for Asian American and Native Hawaiian and Pacific Islander (NHPI) people are usually combined, hiding vast differences in cancer risk. New disaggregated data analyzed by researchers at the American Cancer Society (ACS) show that Native Hawaiian women have a 27% higher breast cancer...
ASCENT-04 Exploratory Analysis: Sacituzumab Govitecan Plus Pembrolizumab Improves PFS2, Delays Next Treatment
First-line treatment with the antibody-drug conjugate sacituzumab govitecan-hziy plus pembrolizumab led to a longer progression-free survival after next line of treatment—ie, progression-free survival–2 (PFS2)—than chemotherapy plus pembrolizumab in patients with previously untreated,...
Spartalizumab-Based Triplet Improves Long-Term Overall Survival in BRAF V600–Mutant Melanoma
The addition of spartalizumab to dabrafenib and trametinib demonstrated a long-term survival benefit in patients with BRAF V600–mutant metastatic melanoma, according to the final overall survival analysis from the phase III COMBI-I trial published in the Journal of Clinical Oncology. “[T]he...
Sociological Study Explores the Concept of ‘Temporal Misalignment’ Among Patients With Terminal Cancer
Scientists are making progress in developing new cancer treatments, but a patient’s experience with cancer is shaped by more than medicine. A new sociological study has found that conflicting medical, work, and family timelines compound inequality, draining resources and displacing goals for even...
MD Anderson President Announces Retirement, Shares Leadership Transition Plans
The University of Texas (UT) MD Anderson Cancer Center is recognizing the leadership of President Peter WT Pisters, MD, following his announced plan to retire from MD Anderson to focus on the next chapter of his career. The UT System Board of Regents and Chancellor John M. Zerwas, MD, have named...
High-Risk Prostate Cancer: GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
In patients with high-risk prostate cancer receiving long-term androgen-deprivation therapy (ADT), pelvic and prostate external-beam radiation therapy (EBRT) at 80 Gy improved progression-free survival compared with conventional 70-Gy radiotherapy, according to findings from the multicenter phase...
Osimertinib Plus Chemotherapy Significantly Extends Progression-Free Survival in EGFR/TP53-Mutated NSCLC
Adding chemotherapy to first-line osimertinib more than doubled median progression-free survival in patients with advanced EGFR-mutated non–small cell lung cancer (NSCLC) harboring concurrent TP53 mutations. The findings come from a phase III randomized trial led by Zhou et al and published in...
Radiation to the Thymus in NSCLC Treatment May Increase Risk of Metastasis
Radiation to the thymus was found to be associated with worse outcomes in patients with non–small cell lung cancer (NSCLC), leading to an increased risk of metastasis, according to findings published in the Annals of Oncology. “The thymus is currently not routinely treated as an important organ...
The 2026 ASCO Annual Meeting Geriatric Oncology Update: The Next Challenge Is Implementation
For more than a decade, geriatric oncology has evolved from a niche discipline into an evidence-based component of high-quality cancer care. Landmark randomized trials, including the Geriatric Assessment for Patients 70 Years and Older Starting Cancer Treatment (GAP70+) trial,1 the Geriatric...
Two Studies Build Evidence Supporting the Use of ctDNA as an Early Endpoint
Investigators from Friends of Cancer Research (Friends) recently published two manuscripts supporting the use of circulating tumor DNA (ctDNA) as an early endpoint for regulatory decision-making. The first article, published by Andrews et al in the Journal of Liquid Biopsy, aggregated data from...
Additional Safety Analysis of DESTINY-Breast05: What Did It Show?
An additional safety analysis of the global phase III DESTINY-Breast05 trial evaluating the HER2-directed antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) has further established the pulmonary safety profile of T-DXd with radiotherapy, according to Michael Untch, MD, PhD, of Helios...
High-Dose Vitamin D3 Does Not Improve PFS in Metastatic Colorectal Cancer
Adding high-dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer (mCRC), according to results from the phase III SOLARIS trial led by Kimmie Ng, MD, MPH, and colleagues and...
FDA Approves Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia
Today, the U.S. Food and Drug Administration (FDA) approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with essential thrombocythemia, making it the first new FDA-approved treatment for essential thrombocythemia in nearly 3 decades. Ropeginterferon alfa-2b-njft has been...
Biomarker Guides Treatment Sequencing, Predicts Outcomes in BRAF-Mutated Metastatic Melanoma
Using a blood test to track thymidine kinase activity may help determine optimal first-line treatment for patients with BRAF V600–mutated metastatic melanoma, according to findings published in Clinical Cancer Research. "The results suggest that thymidine kinase activity may help identify which...
FDA Approves Rusfertide for Erythrocytosis in Adults With Polycythemia Vera
On August 28, the U.S. Food and Drug Administration (FDA) approved rusfertide (Mimrylo) for the treatment of erythrocytosis in adults with polycythemia vera (PV). Rusfertide is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to...
Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors
According to findings from the prospective multicenter LAANTERN study reported by Leuthardt et al in the Journal of Clinical Oncology, laser interstitial thermal therapy (LITT) may offer a minimally invasive cytoreductive option for selected patients with primary and metastatic brain tumors, with...
Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer
A tissue-free circulating tumor DNA (ctDNA) assay was strongly prognostic for recurrence in patients treated for triple-negative breast cancer and provided a lead time to recurrence comparable to that of a multivariant tumor-informed assay, according to findings from a prognostic study published by ...
cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions
A blood-based assay combining cell-free DNA (cfDNA) fragmentomics with droplet digital PCR–based methylation analysis improved detection of early-stage colorectal cancer (CRC) and precancerous lesions, according to findings presented at the 2026 ASCO Breakthrough meeting in Singapore. In this...
In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles
A comparative study of the cancer clinical trial portfolios supported by federal funding vs industry funding reveals they have distinct, interdependent roles in cancer research. The findings were published by Unger et al in JAMA Oncology. The analysis found that, whereas industry trials were more...
Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer
Researchers have reported that a chemotherapy-free combination of four targeted therapies showed encouraging results in patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer, offering a potential first-line treatment option that may be more convenient for some...
ASCO Remembers Dr. Harold P. Freeman, Preeminent Health Equity Expert and Pioneer of Patient Navigation
ASCO joins the oncology community in mourning the death of Harold P. Freeman, MD, a world-renowned expert on and advocate for health equity and the pioneer of patient navigation services in oncology. Dr. Freeman passed away on August 11, 2026; he was 93. After completing medical training at Howard ...
Prostate Cancer: NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT
In the international phase III NRG-GU005 trial, stereotactic body radiotherapy (SBRT) improved bowel-related quality of life vs moderately hypofractionated intensity-modulated radiotherapy (IMRT) in patients with favorable intermediate-risk prostate cancer. However, Ellis et al reported in JAMA...
WashU Medicine Appoints New Chief of Head and Neck Surgery
Andrés M. Bur, MD, FACS, has been named Chief of the Division of Head and Neck Surgery in the Department of Otolaryngology–Head & Neck Surgery at WashU Medicine and Co-Director of the Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at Siteman Cancer Center, based at Barnes-Jewish...
Expanded EHR Data May Improve Prediction of Early Adverse Events After AML Induction Chemotherapy
Patients with acute myeloid leukemia (AML) frequently experienced unplanned hospital readmission or death within 30 days after discharge following induction chemotherapy, according to findings reported by Chae et al in JCO Clinical Cancer Informatics. The investigators found that incorporating...
